secwatch / observer
8-K filed June 5, 2026, 7:05 AM ET ticker MCRB CIK 0001609809
other material confidence high sentiment positive materiality 0.75

Seres receives $25M milestone buyout from Nestlé; restructures lease to cut costs, extends cash runway into Q1 2027

Seres Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Seres Therapeutics, Inc. amended Lease Amendment with 101 CPD LLC valued at approximately $33.9 million (effective 2026-06-04).

Action
amendment
Agreement
lease
Counterparty
101 CPD LLC
Value
approximately $33.9 million
Effective
2026-06-04
Exact text from the filing
On June 4, 2026, the Company entered into the First Amendment to Lease (the “Lease Amendment”) with 101 CPD LLC (f/k/a HCP/King 101 CPD LLC), a Delaware limited liability company (the “Landlord”), which amends the Lease Agreement, dated September 22, 2021, by and between the Company and the Landlord (as amended, the “Lease”), pursuant to which the Company leases approximately 82,714 rentable square feet of office and laboratory space located at 101 CambridgePark Drive, Cambridge, Massachusetts (the “Existing Premises”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Seres Therapeutics, Inc. amended APA Amendment with Société des Produits Nestlé S.A. valued at $25.0 million (effective 2026-06-02).

Action
amendment
Agreement
asset purchase
Counterparty
Société des Produits Nestlé S.A.
Value
$25.0 million
Effective
2026-06-02
Exact text from the filing
On June 2, 2026, Seres Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 (the “APA Amendment”) to the Asset Purchase Agreement, dated as of August 5, 2024 (as previously amended by that certain Letter Agreement, dated September 30, 2024 and that certain Letter Agreement, dated December 31, 2024, the “Purchase Agreement”), by and between the Company and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“SPN”).
View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-258366
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.